[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366942-105":59,"doc-detail-366942-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","gator1-complex-controls-cisplatin-sensitivity","GATOR1 complex controls cisplatin sensitivity","","Cisplatin remains a frontline chemotherapy for many epithelial cancers, but drug resistance limits effective treatment. Although many resistance factors have been reported, dependable biomarkers for cisplatin response are still lacking. This study evaluates intrinsic and acquired cisplatin resistance by comparing non-cancerous BEAS-2B cells with GATOR1 deletions to non-small cell lung cancer lines with acquired resistance. GATOR1 deletions increase cisplatin efflux transporter ATP7A and reduce influx transporters CTR2 and LRRC8A, decreasing drug accumulation and cisplatin-DNA adduct formation. The cells show strengthened DNA damage responses and elevated mTORC1 activity, and cisplatin sensitivity can be restored by GATOR1 component overexpression and/or mTORC1 inhibition. Transcriptomic profiling further reveals new signatures linked to GATOR1 function and cisplatin resistance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/gator1-complex-controls-cisplatin-sensitivity/366942/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/gator1-complex-controls-cisplatin-sensitivity/366942.png","ImageObject",300,407,{"name":92,"@type":93},"CatatanPagi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address about cisplatin treatment?","Question",{"text":112,"@type":113},"Cisplatin is widely used, but resistance—both intrinsic and acquired—reduces treatment effectiveness. Reliable predictive biomarkers for drug response are also still missing.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do GATOR1 deletions affect cisplatin transport and intracellular drug levels?",{"text":117,"@type":113},"Deleting any GATOR1 member increases ATP7A-mediated cisplatin efflux and decreases the influx transporters CTR2 and LRRC8A. This limits cisplatin accumulation and reduces cisplatin-DNA adduct formation.",{"name":119,"@type":110,"acceptedAnswer":120},"How can cisplatin sensitivity be restored in resistant cells?",{"text":121,"@type":113},"Overexpressing GATOR1 components and/or treating with an mTORC1 inhibitor restores cisplatin sensitivity. GATOR1 deletions also correlate with enhanced DNA damage response and higher mTORC1 activity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},366942,1790258886,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090894170,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nGATOR1 complex controls cisplatin sensitivity  \nZhenrui Pan 1,2, Hanxiao Zhang1,3, Xia Xiao 1,3, Catherine Brenner1 and Svetlana Dokudovskaya 1 ✉  \n© The Author(s) 2025  \n\n| | Cisplatin administration is the primary chemotherapy approach for many epithelial cancers. However, resistance to this drug poses a signiﬁcant challenge to effective treatment. Despite the identiﬁcation of numerous factors associated with resistance, reliable biomarkers predicting drug response remain elusive. Previously, low expression of the NPRL2 tumor suppressor was linked tocisplatin resistance. NPRL2, along with NPRL3 and DEPDC5, forms the GATOR1 complex, an upstream regulator of the mTORС1, the function of which is perturbed in many cancers, particularly those resistant to cisplatin. Here, we compare non-cancerous bronchial epithelium BEAS-2B cells with GATOR1 deletions, serving as a model of intrinsic cisplatin resistance, with non-small cell lung cancer lines A549, H460, and H1975 with acquired resistance to the drug. We found that deletion of any GATOR1 member, not solely NPRL2, promotes cisplatin resistance, whereas their overexpression renders cells sensitive to the drug. In cells with GATOR1 deletions, expression of the ATP7A transporter required for cisplatin efﬂux is increased, while expression of cisplatin inﬂux transporters CTR2 and LRRC8A is downregulated, especially after treatment with the drug. This hinders drug accumulation in cells, resulting in the formation of fewer cisplatin-DNA adducts. Simultaneously, these cells exhibit enhanced DNA damage response and mTORC1 activity. Overexpression of GATOR1 components and/or concomitant treatment with an mTORC1 inhibitor restores sensitivity to cisplatin. Transcriptomic analysis of GATOR1-deleted BEAS-2B cells, treated or not with the drug, identiﬁes new signatures important for understanding GATOR1 function and its role in cisplatin resistance. Thus, GATOR1 not only participates in the cellular response to amino acid availability but also plays a role in resistance to DNA-damaging anticancer drugs. This novel function of GATOR1 should be taken into account when developing new strategies to combat chemoresistance. |  | |\n| --- | --- | --- | --- |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n| |  |  | |\n|  | Cell Death and Disease (2026)17:58; [https://doi.org/10.1038/s41419-025-08392-4](https://doi.org/10.1038/s41419-025-08392-4) |  |  |\n|  |  |  |  |\n\nINTRODUCTION  \nCisplatin was approved by the FDA as an anticancer agent in 1978 and has since remained one of the most widely used drugs for treating various carcinomas, including those derived from the bladder, testes, cervix, breast, and ovaries [1, 2] . Additionally, cisplatin is the standard ﬁrst-line treatment for lung cancer, the leading cause of cancer-related deaths (17%) globally, the most prevalent cancer type in men, and the third most common in women [3] . Lung cancer is broadly classiﬁed into two major groups: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC accounting for approximately 80–85% of all cases. NSCLC patients generally exhibit lower sensitivity tocisplatin compared to those with SCLC [4] .  \nCisplatin and its derivatives enter cells by passive diffusion and by active transport through volume-regulated anion channels [5] and copper inﬂux transporters [6] . In the cytoplasm, cisplatin becomes aquated due to lower chloride concentrations compared to the bloodstream. Subsequently, this highly electrophilic molecule interacts with nucleic acids, proteins, and lipids [7] .  \nThe primary targets of cisplatin are nuclear and mitochondrial DNA, where the drug forms intra- and interstrand crosslinks with purine bases. If such DNA damage is not resolved by DNA repair pathways, it imped","cbCaiikS39QTALkH","https://ap.wps.com/l/cbCaiikS39QTALkH","pdf",3759304,18,"English","# Introduction\n## Cisplatin use and resistance\n## Cellular uptake and molecular targets\n## Mechanisms of resistance and mTORC1 link","[{\"question\":\"What problem does the study address about cisplatin treatment?\",\"answer\":\"Cisplatin is widely used, but resistance—both intrinsic and acquired—reduces treatment effectiveness. Reliable predictive biomarkers for drug response are also still missing.\"},{\"question\":\"How do GATOR1 deletions affect cisplatin transport and intracellular drug levels?\",\"answer\":\"Deleting any GATOR1 member increases ATP7A-mediated cisplatin efflux and decreases the influx transporters CTR2 and LRRC8A. This limits cisplatin accumulation and reduces cisplatin-DNA adduct formation.\"},{\"question\":\"How can cisplatin sensitivity be restored in resistant cells?\",\"answer\":\"Overexpressing GATOR1 components and/or treating with an mTORC1 inhibitor restores cisplatin sensitivity. GATOR1 deletions also correlate with enhanced DNA damage response and higher mTORC1 activity.\"}]","GATOR1 complex controls cisplatin sensitivity | PDF",1790168311,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1297b93cd0b964425a2509b844e13c46.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/055deaf956da71075e560e6736d2c8ee.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b3f78c3b74ca91e2239cec7ecd46b48.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f034784c74fc956fd1a7adfc5bdf8629.webp",980,1301]